August 2007
Worldwide Biotech;Aug2007, Vol. 19 Issue 8, p4
Trade Publication
The article reports that the CH-1504 bioequivalency study was initiated by the Chelsea Therapeutics International, Ltd. in Charlotte, North Carolina. The study was conducted at Swiss Pharma in Basel, Switzerland. It was noted that the preclinical and clinical data were expected to enable the company to initiate Phase II trials of CH-1504 in RA during the fourth quarter of 2007. Among the diseases that may benefit from the compound includes psoriasis, inflammatory bowel disease and cancer.


Related Articles

  • CLINIC ROUNDUP.  // BioWorld Today;10/30/2008, Vol. 19 Issue 212, p6 

    This section offers news related to clinical trials. Dosing of ANA598 in patients chronically infected with hepatitis C virus has been started by Anadys Pharmaceuticals Inc. in a Phase Ib study. Enrollment has been completed in Chelsea Therapeutics International Limited's Phase II trial...

  • Clinic Roundup.  // BioWorld Today;1/24/2011, Vol. 22 Issue 15, p3 

    The article presents updates on clinical trials conducted by biotechnology companies. The data on the Phase II trial of telatinib in patients with metastatic stomach cancer supported the potent nature of the antiangiogenic agent developed by ACT Biotech Inc. Data from a safety extension study...

  • Chelsea's Droxidopa Flameout: Hope Alive for Second Phase III. Hollingsworth, Catherine // BioWorld Today;9/25/2009, Vol. 20 Issue 185, p1 

    The article reports on a decline in the value of shares owned by Chelsea Therapeutics International. Shares of the company declined by 61% after news that its most advanced production, droxidopa, for low blood pressure failed in a Phase II study. The drug is being tested in patients with...

  • Chelsea completes enrollment for Phase II hypotension trial.  // PharmaWatch: Biotechnology;Jan2009, Vol. 8 Issue 1, p5 

    The article reports on the patient enrollment completed by Chelsea Therapeutics International Ltd. in its Phase II trial of Droxidopa in patients with intradialytic hypotension in the U.S. The trial is a multi-center, double-blind, placebo controlled study that compared 400 milligrams (mg) and...

  • Ongoing Clinical Trials. Galandiuk, S. // Digestive Surgery;2004, Vol. 21 Issue 4, p325 

    The section presents information on ongoing clinical trials related to oncology and inflammatory bowel disease, as of July 2004. A randomized controlled trial of colorectral polyp and cancer prevention is being conducted by John Burns. A trial comparing laparoscopic and open surgery for rectal...

  • Inflammatory bowel disease III.  // Gut;Jul2012 Supplement, Vol. 61, pA389 

    The article presents abstracts on medical topics of Great Britain which include the clinical trials on inflammatory bowel disease, efficacy of the faecal lactoferrin on the inflammatory bowel disease and the results of cytomegalovirus colitis on patients.

  • An Integrated Paediatric Population PK/PD Analysis of dDAVP: How do PK Differences Translate to Clinical Outcomes? Michelet, Robin; Dossche, Lien; Van Herzeele, Charlotte; De Bruyne, Pauline; Gasthuys, Elke; Van Bocxlaer, Jan; Vande Walle, Johan; Vermeulen, An // Clinical Pharmacokinetics;Jan2020, Vol. 59 Issue 1, p81 

    Introduction: The bioequivalence of two formulations of desmopressin (dDAVP), a vasopressin analogue prescribed for nocturnal enuresis treatment in children, has been previously confirmed in adults but not in children. In this study, we aimed to study the pharmacokinetics (PK) and...

  • Colorectal Cancer in IBD Patients. Stormont, James M; Shah, Ashok N; Sharma, Anil K; Saubermann, Lawrence J; Farmer, Richard G // American Journal of Gastroenterology;Sep2013, Vol. 108 Issue 9, p1535 

    A letter to the editor is presented in response to the article regarding colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD).

  • Inflammatory bowel disease increased risk for non-melanoma skin cancer.  // Hem/Onc Today;11/25/2009, Vol. 10 Issue 22, p15 

    The article discusses a nested case control study led by Dr. Millie Long of the University of North Carolina about the risk of non-melanoma skin cancer on patients with inflammatory bowel disease.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics